Looks like Kintor finished enrollment and dosing of phase 1 for gt20029 in China. Chat 8/9/2022
The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.
View this post in the Community →
Similar Community Posts Join
5 / 362 resultscommunity GT20029 and PP405 the new fin and min that we been waiting for ?
PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.
community Difference: GT20029 vs CosmeRNA
GT20029 and CosmeRNA are both potential hair loss treatments; GT20029 breaks down the androgen receptor, while CosmeRNA prevents its production. Continuous use is needed, but less frequently than current treatments like Minoxidil and Finasteride.
community Kintor Pharma Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World’s First Topical Use PROTAC Compound
The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.
community The closest thing to a cure before hair cloning or genetic via?
The conversation discusses using finasteride or dutasteride to reduce DHT, CosmeRNA to target androgen receptors, and Minoxidil as a vasodilator for hair growth. The regimen aims to maintain hair by addressing DHT-AR ratio and continuous Minoxidil use.
community End of Hair loss ( AGA ) ? Since they produce it in china probably we don’t need to wait other 10 yrs😁
GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.
Related Research
6 / 15 results
research Updates in Treatment for Androgenetic Alopecia
New treatments for hair loss include low-dose oral minoxidil, light therapy, and innovative therapies targeting hair growth mechanisms.
research Topical solutions for androgenetic alopecia: evaluating efficacy and safety
Topical treatments for hair loss can be effective but need careful safety evaluation.
research Pathophysiology of Androgenetic Alopecia and Implications for Treatment: An Overview of Current Literature
Androgenetic alopecia (AGA) is a prevalent form of hair loss driven by genetic, hormonal, and environmental factors, with dihydrotestosterone (DHT) playing a key role in hair follicle miniaturization. Current treatments, such as finasteride and minoxidil, target androgen pathways to mitigate hair thinning. Emerging therapies like platelet-rich plasma and low-level laser therapy show potential but need further validation. The condition involves complex interactions, including inflammation and changes in lipid metabolism, which exacerbate hair loss. Future treatment strategies may benefit from a broader approach, incorporating inflammation modulation and regenerative techniques like stem cell therapy, to enhance efficacy and address systemic health implications.
research Androgens/Androgen Receptor in the Management of Skin Diseases
Understanding how androgens and their receptors work can lead to improved treatments for skin diseases.
research Recent Advances in Drug Development for Hair Loss
New treatments for hair loss show promise with advanced therapies and better targeting.
research Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a multicenter, randomized, double-blind, placebo-controlled phase 2 study
GT20029 helps regrow hair in men with hair loss and is well-tolerated.